Multicenter Phase IB trial of carboxyamidotriazole orotate (CTO) combined with temozolomide (TMZ) for recurrent glioblastoma (GBM) and other malignant gliomas (MG)

Authors :: Elena Pentsova
Linda M Bavisotto
Malbora Manne
Xuling Lin
Mariza Daras
Igor T. Gavrilovic
Antonio Omuro
Lisa M. DeAngelis
Jessica Hansen
Thomas Kaley
Ingo K. Mellinghoff
Andrew T. McKeown
Greg Gorman
Michael Lamson
Rashida A. Karmali
Source :: Journal of Clinical Oncology. 34:2064-2064
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: 2064Background: CTO is an oral inhibitor of non-voltage-dependent calcium signaling that results in simultaneous modulation of several receptor-mediated calcium-dependent signaling pathways. This s...

Subjects :: Cancer Research
Temozolomide
business.industry
Recurrent glioblastoma
macromolecular substances
Oncology
Cancer research
Medicine
Carboxyamidotriazole Orotate
Signal transduction
business
Nuclear medicine
medicine.drug
Calcium signaling

Tools